New drug dostarlimab shows promise in early trial for advanced cancers

NCT ID NCT02715284

Ongoing Disease control Sponsor: Tesaro, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times

Summary

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side effects, and in later parts, it will see if the drug can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Birmingham, Alabama, 35233, United States
GSK Investigational Site

Goodyear, Arizona, 85338, United States
GSK Investigational Site

Scottsdale, Arizona, 85258, United States
GSK Investigational Site

Fayetteville, Arkansas, 72703, United States
GSK Investigational Site

Encinitas, California, 92024, United States
GSK Investigational Site

La Jolla, California, 92093, United States
GSK Investigational Site

Los Angeles, California, 90095, United States
GSK Investigational Site

Newport Beach, California, 92663, United States
GSK Investigational Site

San Francisco, California, 94115, United States
GSK Investigational Site

San Marcos, California, 92069, United States
GSK Investigational Site

Santa Monica, California, 90403, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20007, United States
GSK Investigational Site

Miami, Florida, 33136, United States
GSK Investigational Site

Tampa, Florida, 33612, United States
GSK Investigational Site

Augusta, Georgia, 30912, United States
GSK Investigational Site

Chicago, Illinois, 60637, United States
GSK Investigational Site

Fairway, Kansas, 66205, United States
GSK Investigational Site

Scarborough, Maine, 04074, United States
GSK Investigational Site

Baltimore, Maryland, 21231, United States
GSK Investigational Site

Boston, Massachusetts, 02114, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Detroit, Michigan, 48201, United States
GSK Investigational Site

Kansas City, Missouri, 64111, United States
GSK Investigational Site

Farmington, New Mexico, 87401, United States
GSK Investigational Site

Albany, New York, 12208, United States
GSK Investigational Site

Brooklyn, New York, 11203, United States
GSK Investigational Site

Jamaica, New York, 11432, United States
GSK Investigational Site

New York, New York, 10016, United States
GSK Investigational Site

Charlotte, North Carolina, 28204, United States
GSK Investigational Site

Cleveland, Ohio, 44106, United States
GSK Investigational Site

Columbus, Ohio, 43210, United States
GSK Investigational Site

Hilliard, Ohio, 43026, United States
GSK Investigational Site

Hilliard, Ohio, 43210, United States
GSK Investigational Site

Oklahoma City, Oklahoma, 73104, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19111, United States
GSK Investigational Site

Providence, Rhode Island, 02905, United States
GSK Investigational Site

Dallas, Texas, 75230, United States
GSK Investigational Site

Dallas, Texas, 75290-9032, United States
GSK Investigational Site

San Antonio, Texas, 78229, United States
GSK Investigational Site

Salt Lake City, Utah, 84112, United States
GSK Investigational Site

Charlottesville, Virginia, 22903, United States
GSK Investigational Site

Seattle, Washington, 98104, United States
GSK Investigational Site

Seattle, Washington, 98195, United States
GSK Investigational Site

Spokane, Washington, 99202, United States
GSK Investigational Site

Spokane, Washington, 99204, United States
GSK Investigational Site

Milwaukee, Wisconsin, 53226, United States
GSK Investigational Site

São Paulo, 01246-000, Brazil
GSK Investigational Site

Calgary, Alberta, T2N 4N2, Canada
GSK Investigational Site

Edmonton, Alberta, T6G 1Z2, Canada
GSK Investigational Site

Kelowna, British Columbia, V1Y 5L3, Canada
GSK Investigational Site

Vancouver, British Columbia, V5Z 4E6, Canada
GSK Investigational Site

Hamilton, Ontario, L8V 5C2, Canada
GSK Investigational Site

London, Ontario, N6A 4L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Montreal, Quebec, H2L 4M1, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Hořovice, 26831, Czechia
GSK Investigational Site

Zlín, 762 75, Czechia
GSK Investigational Site

Copenhagen, DK- 2100, Denmark
GSK Investigational Site

Odense C, 5000, Denmark
GSK Investigational Site

Caen, 14076, France
GSK Investigational Site

Lille, 59000, France
GSK Investigational Site

Marseille, 13273, France
GSK Investigational Site

Paris, 75571, France
GSK Investigational Site

Paris, 75908, France
GSK Investigational Site

Saint-Herblain, 44805, France
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Milan, 20132, Italy
GSK Investigational Site

Milan, 20133, Italy
GSK Investigational Site

Milan, 20141, Italy
GSK Investigational Site

Modena, 41100, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Roma, 00144, Italy
GSK Investigational Site

Verona, 37134, Italy
GSK Investigational Site

Gdynia, 81-519, Poland
GSK Investigational Site

Lublin, 20-090, Poland
GSK Investigational Site

Olsztyn, 10-513, Poland
GSK Investigational Site

Olsztyn, 10-561, Poland
GSK Investigational Site

Torun, 87-100, Poland
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Barcelona, 8035, Spain
GSK Investigational Site

Girona, 08907, Spain
GSK Investigational Site

Girona, 17007, Spain
GSK Investigational Site

Madrid, 28027, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Madrid, 28050, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

Pamplona, 31008, Spain
GSK Investigational Site

Santiago de Compostela, 15706, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Valencia, 46009, Spain
GSK Investigational Site

Valencia, 46010, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Aberdeen, AB25 2ZN, United Kingdom
GSK Investigational Site

London, SE1 9RT, United Kingdom
GSK Investigational Site

London, SW3 6JJ, United Kingdom
GSK Investigational Site

London, W1G 6AD, United Kingdom
GSK Investigational Site

London, W1T 7HA, United Kingdom
GSK Investigational Site

Manchester, M20 4BX, United Kingdom
GSK Investigational Site

Newcastle upon Tyne, NE7 7DN, United Kingdom
GSK Investigational Site

Oxford, OX3 7LE, United Kingdom
GSK Investigational Site

Sutton, SW36JJ, United Kingdom

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dostarlimab (a drug that helps the immune system attack cancer cells)

What this could lead to

If this trial succeeds, it could show that dostarlimab is a safe and effective treatment option for people with advanced solid tumors who have run out of other options.

What could go wrong

This is an early phase 1 trial, so the main goal is safety, not proof of effectiveness. The drug may not shrink tumors or could cause significant side effects like immune-related inflammation.

Conditions

The condition(s) this trial relates to.

endometrial cancer neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS NEOPLASMS